10-K: Interpace Biosciences Restates Financials Amid PancraGEN Uncertainty, Eyes Strategic Alternatives

Interpace Biosciences restates prior financial statements due to royalty accrual errors and navigates challenges including a potential non-coverage decision for its PancraGEN test.

Summary

• Interpace Biosciences has restated its prior period consolidated financial statements due to errors in royalty expense accruals.
• The restatement impacts the Annual Reports on Form 10-K for the years ended December 31, 2015 through 2023, and the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2024, June 30, 2024, and September 30, 2024.
• A material weakness in internal control over financial reporting was identified as a result of the restatement.
• The company is facing uncertainty regarding Medicare coverage for its PancraGEN test, with a new LCD establishing non-coverage initially set to take effect but later delayed until April 24, 2025.
• In response to the potential loss of PancraGEN coverage, Interpace Biosciences has approved a restructuring plan to reduce operating costs, with expected annual savings of $12.5 million to $14.5 million.
• The company is exploring strategic alternatives and dilutive/non-dilutive funding options to enhance liquidity.
• Revenue for the year ended December 31, 2024, increased by 17% to $46.9 million, compared to $40.0 million for the year ended December 31, 2023.
• Operating income from continuing operations was $8.1 million for the year ended December 31, 2024, compared to $4.0 million for the year ended December 31, 2023.
• The company had cash and cash equivalents of $1.5 million as of December 31, 2024.
• Two private equity firms control 84% of the company's outstanding shares on an as-converted basis.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue and operating income increased, the restatement of financials and uncertainty around PancraGEN coverage create significant concerns. The company is taking steps to address these challenges, but the overall outlook is uncertain.

Positives

• Revenue increased by 17% to $46.9 million in 2024, driven by increased test volumes.
• Operating income rose to $8.1 million in 2024, reflecting improved profitability.
• The company has a restructuring plan in place to mitigate the impact of potential PancraGEN coverage loss.
• CMS delayed the implementation of the Genetic Testing for Oncology LCD (L39365) from February 23, 2025 until April 24, 2025.

Negatives

• Prior period financial statements were materially misstated, requiring a restatement.
• A material weakness in internal control over financial reporting was identified.
• The company faces uncertainty regarding Medicare coverage for its PancraGEN test.
• The company has a significant accumulated deficit.

Risks

• The company's ability to maintain being a profitable operating company is dependent upon its ability to continue to generate revenues and/or obtain financing adequate to support its cost structure.
• The potential loss of PancraGEN reimbursement could negatively impact the company's liquidity.
• The company depends on a few payers for a significant portion of its revenue for its clinical services.
• The company may not be able to successfully implement future restructuring activities or other significant organizational changes.
• The delisting of the company's common stock from Nasdaq and potential delisting from OTCQX has adversely affected its common stock and business and financial condition.
• The company may be subject to securities litigation, which is expensive and could divert management's attention.

Future Outlook

The company is exploring strategic alternatives and dilutive/non-dilutive funding options to enhance liquidity and is re-evaluating certain parts of the Restructuring Plan and will determine what parts will or will not be postponed or cancelled.

Management Comments

• The Company stated that the change of effective date will allow the Trump administration time to fully review the proposed policy changes, re-evaluate for themselves the supporting clinical evidence for the PancraGEN assay, and fully assess the negative impact on patient care if the currently proposed LCD comes into effect.

Industry Context

The global esoteric molecular diagnostics market is expected to grow to $48.3 billion by 2029, indicating a significant growth opportunity for companies in this space.

Comparison to Industry Standards

• Veracyte, Inc. is a competitor in the thyroid nodule cancer diagnostic test market.
• Quest Diagnostics Incorporated offers a diagnostic test similar to the earlier version of the company's ThyGeNEXT test and distributes the Afirma test in partnership with Veracyte.
• Sonic, Inc. offers ThyroSeq, a diagnostic test that analyzes genetic alterations using next-generation sequencing.
• The University of Pittsburgh Medical Center now offers PancreaSeq, a Next Generation Sequencing panel that focuses on the analysis of mutations in oncogenes and tumor suppressor genes, most of which may help establish the type of pancreatic cyst present and some of which may help establish the presence of malignancy.

Stakeholder Impact

• Shareholders face uncertainty due to the restatement and potential loss of PancraGEN coverage.
• Employees may be affected by the restructuring plan.
• Patients may be impacted by changes in access to PancraGEN testing.

Next Steps

• The company will continue to monitor the CMS decision regarding PancraGEN coverage.
• The company will implement its restructuring plan, if necessary.
• The company will explore strategic alternatives and funding options.
• The company will remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

Interpace Biosciences, restatement, PancraGEN, Medicare, financial results, molecular diagnostics, royalty accrual, internal control, coverage determination, BroadOak, Series C Preferred Stock